Florence Comite
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1790998540
Payments from drug & device makers
Across 123 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Welch Allyn$775
- Amgen$574
- Novo Nordisk$480
- Boehringer Ingelheim$350
- Lilly USA, LLC$324
- AstraZeneca$298
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,79269%
- Education$311%
- Gifts$1764%
- Other$1,05326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Welch Allyn | 1 | $775 |
| Amgen(2 entities) | 28 | $574 |
| Novo Nordisk | 18 | $480 |
| Boehringer Ingelheim | 17 | $350 |
| Lilly USA, LLC | 15 | $324 |
| AstraZeneca | 9 | $298 |
| Baxter Healthcare | 1 | $279 |
| Medical Graphics Corporation | 1 | $176 |
| Antares Pharma, Inc. | 6 | $136 |
| Novartis | 6 | $136 |
| Abbott | 1 | $102 |
| Amarin Pharma, Inc. | 4 | $97 |
| Idorsia Pharmaceuticals US Inc | 3 | $63 |
| Endo Pharmaceuticals Inc. | 2 | $45 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Johnson & Johnson | 1 | $27 |
| Dexcom, Inc. | 1 | $26 |
| Halozyme Inc | 1 | $21 |
| AbbVie | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Metuchen Pharmaceuticals | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NONE$775
- FARXIGA$120
- Ozempic$117
- Epic Stented Tissue Valve$102
How this compares
$4,052 in reported general payments places this provider in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $69,653 |
| MounjaroTirzepatide | 33 | $34,005 |
| TymlosAbaloparatide | 12 | $31,488 |
| FarxigaDapagliflozin Propanediol | 26 | $29,603 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $20,476 |
| Repatha SureclickEvolocumab | 21 | $16,841 |
| TrulicityDulaglutide | 13 | $12,799 |
| Liothyronine Sodium | 30 | $2,142 |
| Testosterone Cypionate | 21 | $933 |
| Rosuvastatin Calcium | 61 | $931 |
| Ezetimibe | 33 | $605 |
| ProgesteroneProgesterone, Micronized | 13 | $585 |
| Levothyroxine Sodium | 33 | $529 |
| Metformin Hcl ErMetformin Hcl | 36 | $462 |
| Anastrozole | 33 | $340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $480 | $69,65354 claims |
| Lilly USA, LLCMounjaro, Trulicity | $324 | $46,80446 claims |
| AstraZenecaFarxiga | $298 | $29,60326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.